Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation; Journal of Controlled Release; Vol. 370
| Parent link: | Journal of Controlled Release.— .— Amsterdam: Elsevier Science Publishing Company Inc. Vol. 370.— 2024.— P. 468-478 |
|---|---|
| Համատեղ հեղինակ: | |
| Այլ հեղինակներ: | , , , , , , , , , , , , , , |
| Ամփոփում: | A critical parameter during the development of protein therapeutics is to endow them with suitable pharmacokinetic and pharmacodynamic properties. Small protein drugs are quickly eliminated by kidney filtration, and in vivo half-life extension is therefore often desired. Here, different half-life extension technologies were studied where PAS polypeptides (PAS300, PAS600), XTEN polypeptides (XTEN288, XTEN576), and an albumin binding domain (ABD) were compared for half-life extension of an anti-human epidermal growth factor receptor 2 (HER2) affibody-drug conjugate. The results showed that extension with the PAS or XTEN polypeptides or the addition of the ABD lowered the affinity for HER2 to some extent but did not negatively affect the cytotoxic potential. The half-lives in mice ranged from 7.3 h for the construct including PAS300 to 11.6 h for the construct including PAS600. The highest absolute tumor uptake was found for the construct including the ABD, which was 60 to 160% higher than the PASylated or XTENylated constructs, even though it did not have the longest half-life (9.0 h). A comparison of the tumor-to-normal-organ ratios showed the best overall performance of the ABD-fused construct. In conclusion, PASylation, XTENylation, and the addition of an ABD are viable strategies for half-life extension of affibody-drug conjugates, with the best performance observed for the construct including the ABD. Текстовый файл AM_Agreement |
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
2024
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://doi.org/10.1016/j.jconrel.2024.04.051 |
| Ձևաչափ: | Էլեկտրոնային Գրքի գլուխ |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=674262 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 674262 | ||
| 005 | 20260727162033.0 | ||
| 090 | |a 674262 | ||
| 100 | |a 20240719d2024 k||y0rusy50 ca | ||
| 101 | 0 | |a eng | |
| 102 | |a NL | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i |b e | |
| 182 | 0 | |a b | |
| 183 | 0 | |a cr |2 RDAcarrier | |
| 200 | 1 | |a Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation |f Jie Zhang, Vitalina Bodenko, Maria Larkina [et al.] | |
| 203 | |a Текст |b визуальный |c электронный | ||
| 283 | |a online_resource |2 RDAcarrier | ||
| 320 | |a References: 31 tit. | ||
| 330 | |a A critical parameter during the development of protein therapeutics is to endow them with suitable pharmacokinetic and pharmacodynamic properties. Small protein drugs are quickly eliminated by kidney filtration, and in vivo half-life extension is therefore often desired. Here, different half-life extension technologies were studied where PAS polypeptides (PAS300, PAS600), XTEN polypeptides (XTEN288, XTEN576), and an albumin binding domain (ABD) were compared for half-life extension of an anti-human epidermal growth factor receptor 2 (HER2) affibody-drug conjugate. The results showed that extension with the PAS or XTEN polypeptides or the addition of the ABD lowered the affinity for HER2 to some extent but did not negatively affect the cytotoxic potential. The half-lives in mice ranged from 7.3 h for the construct including PAS300 to 11.6 h for the construct including PAS600. The highest absolute tumor uptake was found for the construct including the ABD, which was 60 to 160% higher than the PASylated or XTENylated constructs, even though it did not have the longest half-life (9.0 h). A comparison of the tumor-to-normal-organ ratios showed the best overall performance of the ABD-fused construct. In conclusion, PASylation, XTENylation, and the addition of an ABD are viable strategies for half-life extension of affibody-drug conjugates, with the best performance observed for the construct including the ABD. | ||
| 336 | |a Текстовый файл | ||
| 371 | 0 | |a AM_Agreement | |
| 461 | 1 | |c Amsterdam |n Elsevier Science Publishing Company Inc. |t Journal of Controlled Release | |
| 463 | 1 | |d 2024 |t Vol. 370 |v P. 468-478 | |
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a Affibody molecule | |
| 610 | 1 | |a Albumin binding domain | |
| 610 | 1 | |a ABD | |
| 610 | 1 | |a HER2 | |
| 610 | 1 | |a PASylation | |
| 610 | 1 | |a XTENylation | |
| 610 | 1 | |a DM1 | |
| 610 | 1 | |a Affibody-drug conjugate | |
| 610 | 1 | |a Half-life | |
| 701 | 0 | |a Jie Zhang | |
| 701 | 1 | |a Bodenko |b V. V. |c pharmacist |c engineer at Tomsk Polytechnic University |f 1997- |g Vitalina Vasiljevna |9 88553 | |
| 701 | 1 | |a Larkina |b M. S. |g Mariya Sergeevna |f 1984- |c pharmacist |c Professor; Senior Researcher of the Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences |9 22417 | |
| 701 | 1 | |a Bezverkhniaia |b E. A. |c pharmacist |c Research Engineer Tomsk Polytechnic University |f 1994- |g Ekaterina Aleksandrovna |9 22467 | |
| 701 | 0 | |a Tianqi Xu | |
| 701 | 0 | |a Yunqi Liao | |
| 701 | 0 | |a Ayman Abouzayed | |
| 701 | 1 | |a Plotnikov |b E. V. |c chemist |c Associate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences |f 1983- |g Evgeny Vladimirovich |9 16417 | |
| 701 | 1 | |a Tretyakova (Tretjyakova) |b M. S. |c Medical technology specialist |c Research Engineer of Tomsk Polytechnic University |f 1994- |g Maria Sergeevna |9 22127 | |
| 701 | 1 | |a Yuldasheva |b F. Sh. |g Feruza Sherzod kizi | |
| 701 | 1 | |a Belousov |b M. V. |c chemist |c Professor of Tomsk Polytechnic University, Doctor of Pharmaceutical Sciences |f 1963- |g Mikhail Valerievich |9 21924 | |
| 701 | 1 | |a Orlova |b A. M. |c specialist in the field of medical technology |c Senior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D |f 1960- |g Anna Markovna |9 22212 | |
| 701 | 1 | |a Tolmachev |b V. M. |c specialist in the field of medical technology |c Director of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D |f 1961- |g Vladimir Maksimilianovich |9 22210 | |
| 701 | 1 | |a Torbjorn |b G. |g Graslund | |
| 701 | 1 | |a Vorobyeva |b A, |g Anzhelika | |
| 712 | 0 | 2 | |a Томский политехнический университет |c 1991- |9 26305 |4 570 |
| 801 | 0 | |a RU |b 63413507 |c 20240827 | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.1016/j.jconrel.2024.04.051 |z https://doi.org/10.1016/j.jconrel.2024.04.051 | |
| 942 | |c CR | ||